Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial

Autor: Zamagni, Elena a, b, ∗, Oliva, Stefania c, Gay, Francesca c, d, Capra, Andrea d, Rota-Scalabrini, Delia e, D'Agostino, Mattia c, d, Belotti, Angelo f, Galli, Monica g, Racca, Manuela h, Zambello, Renato i, Gamberi, Barbara j, Albano, Domenico k, Bertamini, Luca c, d, Versari, Annibale l, Grasso, Mariella m, Sgherza, Nicola n, Priola, Claudia d, Fioritoni, Francesca o, Patriarca, Francesca p, De Cicco, Gabriella a, b, Villanova, Tania d, Pascarella, Anna q, Zucchetta, Pietro r, Tacchetti, Paola a, Fanti, Stefano s, Mancuso, Katia a, b, Barbato, Simona a, b, Boccadoro, Mario d, Musto, Pellegrino n, t, Cavo, Michele a, b, Nanni, Cristina s
Zdroj: In eClinicalMedicine June 2023 60
Databáze: ScienceDirect